Eskazan, A. E. Et Al. 2014. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. LEUKEMIA RESEARCH , vol.38, no.7 , 781-787.

Eskazan, A. E., Eyice, D., Kurt, E. A., ELVERDİ, T., Yalniz, F. F., Salihoglu, A., ... AR, M. C.(2014). Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. LEUKEMIA RESEARCH , vol.38, no.7, 781-787.

Eskazan, Ahmet Et Al. "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion," LEUKEMIA RESEARCH , vol.38, no.7, 781-787, 2014

Eskazan, Ahmet E. Et Al. "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." LEUKEMIA RESEARCH , vol.38, no.7, pp.781-787, 2014

Eskazan, A. E. Et Al. (2014) . "Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion." LEUKEMIA RESEARCH , vol.38, no.7, pp.781-787.

@article{article, author={Ahmet Emre Eskazan Et Al. }, title={Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion}, journal={LEUKEMIA RESEARCH}, year=2014, pages={781-787} }